摘要
目的:探讨survivin和PTEN在非小细胞肺癌(NSCLC)中的表达情况及其与NSCLC临床生物学行为的关系。方法:应用免疫组织化学方法检测survivin和PTEN在78例NSCLC组织、46例癌旁组织和12例非癌肺良性病变组织中的表达情况,并将结果进行相关性分析。结果:Survivin在非癌良性病变组织、癌旁组织、非小细胞肺癌中的阳性表达率分别是0、10.9%、67.9%,其蛋白表达逐渐增强(P<0.05);非小细胞肺癌中的survivin表达显著高于癌旁肺组织及非癌良性病变组织中的表达(P<0.05)。PTEN在非癌良性病变组织、癌旁组织、非小细胞肺癌中的阳性表达率分别是100%、91.3%、47.4%,其表达逐渐减弱(P<0.05);非小细胞肺癌中的PTEN表达低于癌旁肺组织及非癌良性病变组织中的表达(P<0.05)。survivin蛋白的表达与NSCLC的病理学分级、淋巴结转移、TNM分期有关(P<0.05)。PTEN蛋白的表达与NSCLC的病理学分级、淋巴结转移、TNM分期有关(P<0.05)。Survivin与PTEN表达呈负相关(P<0.05)。结论:Survivin和PTEN在NSCLC中的异常表达与其生物学行为密切相关,survivin在非小细胞肺癌中过度表达,PTEN在非小细胞肺癌中表达降低,并且二者的表达呈负相关,二者可作为NSCLC判断病情和评价预后的参考指标。
Objective: To study the expression of survivin and PTEN in non-small cell lung cancer (NSCLC) and to investigate their correlations with the biological behavior of NSCLC. Methods: Expression of survivin and PTEN proteins was detected by immunohistochemical assay in 78 NSCLC tissues, 46 lung cancer adjacent tissues and 12 benign lung tissues, which entailed subsequent analysis on the correlation. Results: The expression rate of survivin was the lowest in benign lung tissues (0%), followed by the adjacent tissues ( 10. 9% ) and NSCLC tissues (67.9%) ( both P 〈 0.05 ). The expression rate of PTEN was the highest in benign lung tissues ( 100% ) , followed by the adjacent tissues (91.3%) and NSCLC tissues (47.4%) ( both P 〈0. 05 ). The expression of survivin and PTEN was associated with the pathological grading, lymph node metastases and TNM stages ( all P 〈 0.05 ). Furthermore, the expression of survivin correlated negatively with that of PTEN ( P 〈 0.05 ). Conclusion : The aberrant expression of survivin and PTEN in NSCLC may be associated with their biological behaviors. Survivin is over expressed whilst PTEN is down-regulated in NSCLC. Survivin expression correlates negatively with PTEN expression. Both markers could serve as the reference for determination of the disease severity and evaluation of the prognosis of NSCLC.
出处
《广州医学院学报》
2013年第6期1-5,共5页
Academic Journal of Guangzhou Medical College
基金
广东省第一批科学事业费计划项目(2008B030301018)